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Introduction

Case Study

The Chikungunya virus (CHIKV) has
spread like a wildfire in the Americas. Since
its emergence in Sub-Saharan Africa as
early at the 18th century, CHIKV has caused
many isolated outbreaks in Africa,
Southeast Asia, and Australia. Over the last
decade, the vector-borne disease has
inflicted millions of people on islands in the
Indian Ocean, India, and now the Americas
with the aid of viral mutations and
international travel (Weaver and Lecuit,
2015).
The first case of local CHIKV
transmission in the Western Hemisphere
was fairly recent. On the island of St.
Martin in October 2013, an individual
carrying an Asian strain of CHIKV was bitten
by a local mosquito. This mosquito (A.
aegypti) became a local carrier of the
disease. A. aegypti can be found in the
Caribbean, Central America, much of South
America, and the southeastern United
States. There are over 1.2 million reported
cases in the Americas from 2013 to March
2015 (Gaines, 2015). Recently, there have
been 11 CHIKV cases in Florida which were
transmitted by local mosquitos. Further
spread of the virus throughout the
Americas is expected (Weaver & Lecuit,
2015). If a single gene mutation on the
envelope protein occurs (which has
happened on La Reunion Island), it could
significantly boost the spread of the virus
via another mosquito, A. albopictus. A.
albopictus inhabits much of the United
States including Ohio (Miner et al., 2015).
Advanced practice nurses (APN) should
be aware of the clinical signs and
symptoms, pathophysiology, and the
implications for nursing care of CHIKV
because of its recent rapid spread in the
Western Hemisphere. The Centers for
Disease Control and Prevention (CDC) are
expected to add the virus to the list of
notifiable conditions this year (Lindsey et
al., 2015).

A 28 year old woman visited Mumbai, India in September 2010 and received many
mosquito bites. Twelve days into her trip, she experienced a sudden onset of fever, chills,
hyperpigmentation on the bridge of her nose, and severe joint pain in her wrists, ankles,
and neck. She was treated for malaria and her fever resolved after three days with no
recurrence (Schwartz, Giga, & Boggild, 2014).
After her recovery from acute illness, she still experienced considerable joint pain and
restricted range of motion in her wrists, neck, and ankles. She was referred to a tropical
disease unit two and a half months after her initial symptoms because of her persistent
polyarthritis and minimal pain relief with the use of nonsteroidal anti-inflammatory drug,
celecoxib. On physical examination, her vital signs were normal with no
lymphadenopathy, hepatosplenomegaly, or joint effusions. Her complete blood count
was normal with the exception of mildly elevated eosinophils (Schwartz et al, 2014).
Serologic studies revealed nonreactive results for rickettsia and an elevated titer to
chikungunya immunoglobulin G (IgG) antibodies. Dengue IgG antibodies were reactive,
but immunoglobulin M (IgM) antibodies were nonreactive. Because of her persistent
arthralgia and nonreactive dengue IgM antibodies, it was concluded that the dengue IgG
antibodies were a false-positive. She was diagnosed with chikungunya fever and was
prescribed ibuprofen and physical therapy for treatment. Her arthralgia and range of
motion improved over 18 months, but she still had not returned to her baseline after two
years post-infection (Schwartz et al, 2014).

Pathophysiological Process

Nursing Implications
Understanding the pathophysiology of
CHIKV is important when determining
how to prevent the spread of disease and
also when diagnosing, and treating the
disease. Local authorities can prevent
CHIKV by fogging the mosquitoes and by
averting standing water. Understanding
the pathophysiology allows the
practitioner to order the appropriate
diagnostic tests and predict the course of
events in the disease process. The
significance of comprehending the
pathophysiology of CHIKV is most
apparent in the development of
treatments and a vaccine. Treatments
cannot be developed if researchers and
providers do not understand what is
happening at a cellular level. Further
research regarding the cause of the
chronic disease is needed in order to treat
this complication.

•

Due to the increased incidence of
CHIKV in the Americas and
increases in international travel
and globalization, more patients
infected with CHIKV are
presenting to providers in the
United States.

•

CHIKV is often mistaken for
dengue fever and sometimes
malaria, so familiarity with the
signs and symptoms of CHIKV is
important. Dengue fever patients
frequently present with
hemorrhagic symptoms whereas
patients with CHIKV will usually
exhibit long lasting and
debilitating joint pain (Tither,
2014).

•

There is no drug or vaccine to
protect anyone from CHIKV, so
patients should be counseled to
use bug spray, protective clothing,
and mosquito nets as protection
from mosquito bites.

•

If a patient presents with a
possible infectious disease, always
inquire about travel history and
refer to an infectious disease
specialist for treatment if needed.

Signs and Symptoms
•

The acute phase involves a sudden
onset of high fever and joint pain.

•

Headache, myalgia, photophobia,
diarrhea, vomiting, nausea,
hyperpigmentation, mucosal and
dermal lesions

•

40-50% of cases develop a
maculopapular rash.

•

•

90% will experience severe and
often debilitating joint pain. The
pain is usually bilateral and
symmetrical in the hands, wrists,
and ankles as well as larger joints
such as the elbows, knees, and
shoulders (Thiberville et al, 2013).

Refer to the Centers for Disease
Control and Prevention (CDC)
traveler’s website for the most upto-date information on CHIKV
(Tither, 2014).

•

CHIKV will soon have CDC
reporting requirements (Moore,
2015).
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Chikungunya is a vector-borne virus and is spread to humans by the bite of infected A.
aegypti and A. albopictus mosquitos. Humans are the “primary amplifying host” for CHIKV
because mosquitoes become infected when they bite an infected human during their first
week of illness and viremia. There are also maternal-fetal and bloodborne transmission cases
(Staples & Fisher, 2015). Infected mosquitoes are found in tropical and sub-tropical locations
around the world, and most recently, the Americas. The virus is expected to spread
throughout the Americas similar to the current distribution of the dengue virus (Coffey,
Failloux, & Weaver, 2014).
CHIKV is an enveloped, single-stranded- RNA alphavirus. The virus replicates in fibroblasts
of the dermis, then disseminated via the bloodstream to the liver, muscle, lymphoid tissue,
choroid plexus, and joints. CHIKV can be found mostly in skin, muscle, and joint fibroblasts,
but are also within the epithelial and endothelial layers of many organs such the liver and
spleen. Cells that are infected with CHIKV rapidly undergo apoptosis. The incubation period
of CHIKV is about 2-4 days with no prodromal phase. The onset of acute symptoms is sudden.
The acute phase lasts a few days to a couple of weeks. There is a strong and immediate
innate immune response, mainly by interferons and pro-inflammatory cytokines. Acute
infection is also associated with transient lymphopenia and neutropenia (Schwartz & Albert,
2010). The adaptive immune (primarily IgG and IgM antibodies) response can be identified
one week after the onset of symptoms. IgG antibodies will persist for years as protection
from recurrence (Schwartz et al., 2014). Complications from acute illness include
encephalitis especially in neonates and children, as well as cardiovascular disease, hepatitis,
renal disease, pneumonia, respiratory failure, and hemorrhagic disease. The highest
mortality from CHIKV is in neonates, people with underlying medical conditions, and the
elderly. The fatality rate is estimated to be 1 in 1000 (Essackjee, Goorah, Ramchurn,
Cheeneebash, & Walker-Bone, 2013).
Many CHIKV patients experience a chronic disease phase. The hallmark symptom of this
phase is persistent arthralgia or arthritis which can last for months to years (Schwartz &
Albert, 2010). The joint pain was presumed to be the result of an immune-mediated response
similar to that of rheumatoid arthritis, but is not well understood. In addition, macrophages
and monocytes are involved in the clearance of viral debris which triggers a proinflammatory response in the joints. Researchers do not know whether persistent CHIKV
replication or remaining CHIKV antigens or both are responsible for the immune response
(Weaver & Lecuit, 2015).

•

There are some “silent” cases where
no signs and symptoms are
detected (Schwartz & Albert, 2010).

•

The chronic phase involves
persistent arthralgia in multiple
joints. Studies vary on the
proportion of patients who fully
recover after acute illness and those
that exhibit chronic symptoms.

•

CHIKV can cause long-term joint
pain and disability similar to that of
rheumatoid arthritis. The elderly
and females are at a greater risk for
this condition (Essackjee et al.,
2013).

Conclusion
CHIKV is now a global vector-borne
virus affecting 1.2 million people in the
Americas alone. 2500 cases were
reported in the United States, mostly
from recent travelers in 2014 (Gaines,
2015). The CDC provides the greatest
amount of resources to providers
regarding updates on the spread of the
disease and prevention. Nurse
practitioners need to be aware of the
pathophysiology and signs and
symptoms, and prevention of CHIKV in
order to protect and treat patients
properly. Pre-travel counseling about
mosquito bite prevention is the best
way to protect people from CHIKV in
this globalized world.
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